Combined use of systemic colchicine and allopurinol for Behçet disease Hiroshi Goto 1 , Gakushi Matsuura 1 , Naoyuki Yamakawa 1 , Anaberu Okada 1 , Junnichi Sakai 1 , Masahiko Usui 1 1Dept of Ophthalmol, Tokyo Med Coll pp.483-486
Published Date 1995/3/15
DOI https://doi.org/10.11477/mf.1410904220
  • Abstract
  • Look Inside

We treated 20 eyes of 11 patients with Behçet disease with systemic colchicine and allopurinol over a mean period of 10.6 months. All the cases were refractory to conventional colchicine therapy alone. The visual acuity remained stationary or improved in 17 eyes, 85%. The ocular inflammatory attacks decreased from 3.1 to 1.6 in average over a 6-month period. Extraocular manifestations, including oral aphthous ulcer, improved in many cases. Untoward side effects were consistently absent. The findings show the beneficial effect of combined use of systemic colchicine and allopurinol for refractory Behçet disease.

Copyright © 1995, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院